Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US미국에서 백신 접종을 하지 않은 가족 중 단클론 항체를 사용한 COVID-19 예방의 예상 건강 결과 및 비용Randomized Controlled Trial Published on 2022-04-012022-09-11 Journal: JAMA Network Open [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Administered age Casirivimab complementary confirmed COVID-19 case Contact Coverage COVID-19 COVID-19 case COVID-19 infection COVID-19 infections COVID-19 pandemic COVID-19 vaccination death deaths disrupt effective vaccine Effective vaccines eligible Estimated Ethnicity exposure to Health health system Hospitalization hospitalizations household household contact Imdevimab IMPROVE individual Infection intensity mAb mAbs monoclonal antibodies monoclonal antibody Older outcome Postexposure Prophylaxis Probability public health randomized clinical trial reduce reduce costs Sex subcutaneous injection subcutaneous injections susceptible symptomatic infection symptomatic infections threshold thresholds Transmission Vaccination Status Vaccine variant of SARS-CoV-2 [DOI] 10.1001/jamanetworkopen.2022.8632 PMC 바로가기 [Article Type] Randomized Controlled Trial
Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients – A Czech multicenter experienceSARS-CoV-2에 감염된 혈액학적 환자에서 항-SARS-CoV-2 단일클론 중화 항체의 성공적인 조기 사용 - 체코의 다기관 경험Multicenter Study Published on 2022-04-012022-09-12 Journal: Hematological oncology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] administration analyzed anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal neutralizing antibodies Asymptomatic asymptomatic patient bamlanivimab baseline Casirivimab Cohort Combination Course COVID-19 COVID-19 diagnosis COVID-19 mortality COVID-19 symptom Critical death diagnose diagnosed early administration early-stage COVID-19 Efficacy evaluated Final first COVID-19 symptom Follow-up General population hematological Hematological malignancy Imdevimab impair Infection leukemia leukemias lymphoma lymphomas median Mild moderate monoclonal monoclonal antibody monotherapy Mortality multicenter multicentre Neutralizing neutralizing antibody neutralizing monoclonal antibody nine occurred Patient patients plasma positive remained Result SARS-CoV-2 significantly significantly lower Spike protein survival rate therapy treated were recorded [DOI] 10.1002/hon.2974 PMC 바로가기 [Article Type] Multicenter Study
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients신장에서 SARS-CoV-2-중화 단일클론항체 또는 신장-췌장 결합 이식 환자에 대한 초기 경험Article Published on 2022-03-312022-09-11 Journal: Transplant International [Category] MERS, SARS, 변종, 진단, [키워드] Administered analyzed antibodies antiviral drugs appear bamlanivimab clinical outcomes co-primary endpoint co-primary endpoints Combined Contact coronavirus COVID-19 death drug effective Emergency use authorization EUA experience Hospitalization Hospitalized hospitalized patient identify Imdevimab Immunocompromised Immunosuppression IQR kidney Kidney transplantation lymphoma mAb median interval monoclonal antibodies monoclonal antibody Mortality negativity Organ transplant overall mortality Patient PCR negativity positive receive recipient recipients renal function respiratory Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 RT-PCR shown single dose single doses Spike protein Transplant treated Treatment U.S. FDA variant Viral viral spike viral spike protein virus-specific antibodies [DOI] 10.3389/ti.2022.10109 PMC 바로가기 [Article Type] Article
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case SeriesAnti-SARS-CoV-2 단클론항체를 포함한 SARS-CoV-2 감염 혈액병 환자의 종합 치료: 단일 센터 경험 사례 시리즈Article Published on 2022-03-262022-09-11 Journal: Current Oncology [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Analysis antibody Antibody therapy B.1.1.529 B.1.617.2 bamlanivimab benefit best Cancer case sery Casirivimab clearance clinical clinical effectiveness Combination Comprehensive coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient delta variant Diagnosis Effectiveness exacerbated experience FIVE hematologic hematologic malignancies Hematologic malignancy Hematological malignancies high risk Hospitalization Imdevimab Including knowledge lAbel less mAbs monoclonal antibodies monoclonal antibody Mortality off-label omicron Omicron variant oxygen oxygen supplementation Patient Potential receiving reduce reduced reduction in respiratory retrospective risk SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2-infected patient Sery severe acute respiratory syndrome Coronavirus shown Sotrovimab suggested Tolerability Treatment variant [DOI] 10.3390/curroncol29040188 PMC 바로가기 [Article Type] Article
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta VariantSARS-CoV-2 Delta 변이에 감염된 백신 접종 환자에서 Casirivimab/Imdevimab 단일클론항체 치료 효과Article Published on 2022-03-212022-09-11 Journal: Viruses [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome Analysis B.1.617.2 Casirivimab casirivimab/imdevimab Chest Chest computed tomography clinical clinical evolution clinical manifestations Clinical presentations cocktail Computed tomography coronavirus coronavirus 2 Delta delta variant Disease progression early stage early stages Effect effective Efficacy evaluated Evolution FIVE Hospitalized Imdevimab Infection mAb mAbs monoclonal antibodies monoclonal antibody monoclonal antibody treatment Nasopharyngeal swab nasopharyngeal swabs Next-generation sequencing NGS outcomes Patient patients performed prevent disease progression real-time RT-PCR Regression respiratory Respiratory failure Safe SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 submitted Symptom Symptoms thymoma Treatment Vaccine variant variants variants of concern Viral viral load reduction [DOI] 10.3390/v14030650 PMC 바로가기 [Article Type] Article
An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodiesReview Published on 2022-03-182023-07-02 Journal: Indian journal of pharmacology [Category] SARS, [키워드] bamlanivimab Casirivimab COVID-19 etesevimab Imdevimab monoclonal antibodies review Treatment [DOI] 10.4103/ijp.ijp_519_21 PMC 바로가기 [Article Type] Review
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report면역 저하 환자에서 지속되는 SARS-CoV-2 감염 치료 중 렘데시비르 내성 돌연변이의 새로운 출현: 증례 보고Case Reports Published on 2022-03-172022-09-11 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료제, [키워드] absence Antiviral antiviral agent B-cell benefit Case report Casirivimab Course deficiency demonstrated experiment Imdevimab Immunocompromised Immunocompromised patient Immunocompromised patients in vitro increase in indolent limit Mutation Nsp12 patients receiving treatment produced recrudescence Remdesivir reported resistance mutations risk RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 SARS-COV-2 infection specimens Symptom therapy Treatment Viral viral shedding Whole genome sequencing [DOI] 10.1038/s41467-022-29104-y PMC 바로가기 [Article Type] Case Reports
The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case seriesOriginal Research Published on 2022-03-032022-10-30 Journal: International Journal of Emergency Medicine [Category] COVID-19, [키워드] administration Admission adverse event age Analysis antibody bamlanivimab case sery Casirivimab Characteristics Community coronavirus disease COVID-19 COVID-19 infection COVID-19 symptom determine Emergency use authorization EUA follow-up period hospital Hospitalization Imdevimab incidence median Mild moderate monoclonal antibody morbidity Patient pediatric Pediatric patient Pediatric patients Primary outcome reducing required Result retrospective returned safety profile secondary outcome Symptom the patient therapy Two patient [DOI] 10.1186/s12245-022-00414-8 PMC 바로가기 [Article Type] Original Research
Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2SARS-CoV-2 Delta 하위 계통 AY.4.2의 융합성 및 중화 민감도Article Published on 2022-03-012022-09-11 Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단, 치료기술, [키워드] A222V ACE2 ACE2 binding anti-RBD Anti-RBD antibodies antibody AY.4.2 B.1.617.2 binding changes in characterized COVID-19 Delta delta variant Efficacy exhibited Flash fundraising Fusogenicity Imdevimab impair less Lineage monoclonal monoclonal antibodies Mutation N-terminal domain neutralization Neutralizing antibodies NTD omicron reduced SARS-CoV-2 SARS-CoV-2 lineage sensitivity sequenced sera spikes Spread strain tested the antibody the SARS-CoV-2 vaccinated individual vaccinated individuals Vaccines Viral virus was reduced [DOI] 10.1016/j.ebiom.2022.103934 PMC 바로가기 [Article Type] Article
COVID-19 updates: NIH outpatient treatment guidelinesArticle Published on 2022-02-212023-07-08 Journal: The Medical letter on drugs and therapeutics [Category] COVID19(2023년), [키워드] bamlanivimab Casirivimab COVID-19 Efficacy etesevimab Imdevimab molnupiravir Nirmatrelvir Paxlovid REGEN-COV Remdesivir Ritonavir Sotrovimab Veklury